Servier – Learn more about our development portfolio

DEVELOPMENT pipeline

Reinvesting our profit to discover new medicines

At Servier, major investment in R&D (Close to 20% of revenue from brand-name medicines) creates a promising pipeline of innovative projects targeting illnesses with significant unmet medical needs. Our pipeline reflects our ambition to concentrate on the quality and potential of R&D projects, half of which have the potential to become “first-in-class” medicines.

In June 2026, it comprised 60 projects, 37 of which in clinical development and 23 research projects.

Oncology

Neurology

Cardio-metabolic & Venous Diseases

Updated in June 2026

• Oncology

solid tumors

CompoundDarovasertib

TargetPKC

Therapeutic areas

Uveal melanoma
Rare ocular tumor originating from uveal melanocytes; can metastasize, especially to the liver.

Phase

PCD

1/2

CompoundIvosidenib

TargetIDH1

Therapeutic areas

Chondrosarcoma
Malignant tumor forming cartilage, generally of bone origin. Rare cancer of the bile ducts, occurring inside or outside the liver.

Phase

PCD

1/2

CompoundIvosidenib/
+ durvalumab + gemcitabine/cisplatine

TargetIDH1

Therapeutic areas

Cholangiocarcinoma

Phase

PCD

1/2

CompoundTovorafenib

TargetRAF

Therapeutic areas

Glioma
Brain/spinal cord tumor arising from glial (support) cells, with variable aggressiveness.

Phase

PCD

1/2

CompoundTovorafenib

TargetRAF

Therapeutic areas

Solid Tumor

Phase

PCD

1/2

CompoundVorasidenib/
+ temozolomide

TargetIDH1/2

Therapeutic areas

Glioma

Phase

PCD

1/2

CompoundVorasidenib/
+ pembrolizumab

TargetIDH1/2

Therapeutic areas

Glioma

Phase

PCD

1/2

CompoundEmiltatug Ledadotin

TargetB7-H4

Therapeutic areas

Solid Tumor

Phase

PCD

1/2

CompoundS253272

TargetPTK-7

Therapeutic areas

Solid Tumor

Phase

PCD

1/2

CompoundS095018
(in association)

TargetTIM3

Therapeutic areas

Non-small-cell lung cancer

Phase

PCD

1/2

CompoundS095024
(in association)

TargetCD73

Therapeutic areas

Non-small-cell lung cancer

Phase

PCD

1/2

CompoundS095029
(in association)

TargetNKG2A

Therapeutic areas

Non-small-cell lung cancer

Phase

PCD

1/2

CompoundS095029
(in association)

TargetNKG2A

Therapeutic areas

Gastric cancer

Phase

PCD

1/2

CompoundS241656

TargetRAS, RAF

Therapeutic areas

Solid tumors

Phase

PCD

1/2

hematologic malignancies

CompoundIvosidenib/
+ 7+3 (chemotherapy)

TargetIDH1

Therapeutic areas

Acute Myeloid Leukemia

Phase

PCD

1/2

CompoundIvosidenib /
azacitidine / venetoclax

TargetIDH1

Therapeutic areas

Acute Myeloid Leukemia

Phase

PCD

1/2

CompoundIvosidenib

TargetIDH1

Therapeutic areas

Acute Myeloid Leukemia

Phase

PCD

1/2

CompoundS243249

TargetMENIN

Therapeutic areas

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia

Phase

PCD

1/2

CompoundS236220

TargetND*

Therapeutic areas

Hematologic malignancies

Phase

PCD

1/2

CompoundS247567

TargetND*

Therapeutic areas

Hematologic malignancies

Phase

PCD

1/2

• Neurology

CompoundS247240
Chemical entity

TargetBK channel

Therapeutic areas

Fragile X syndrome
is a genetic disorder caused by a mutation in the FMR1 gene, leading to a deficiency of the fragile X mental retardation protein (FMRP).

Phase

PCD

1/2

CompoundS230815
AntiSense Oligonucleotide

TargetKCNT1

Therapeutic areas

KCNT1-related
Developmental and Epileptic Encephalopathies
(DEE) are a group of severe neurological disorders characterized by very early-onset seizures and significant developmental delays.
More on ASO technology

Phase

PCD

1/2

CompoundS233107

TargetND*

Therapeutic areas

Movement disorders

Phase

PCD

1/2

• Cardiometabolism & Venous diseases

CompoundIvabradine
(new formulation)

Target

Therapeutic areas

Heart Failure

Phase

PCD

1/2

CompoundDapagliflozin / Bisoprolol

Target

Therapeutic areas

Heart Failure

Phase

PCD

1/2

CompoundBisoprolol / Perindopril / Indapamide / Amlodipine

Target

Therapeutic areas

Hypertension

Phase

PCD

1/2

CompoundPerindopril / Indapamide SR / Amlodipine

Target

Therapeutic areas

Hypertension

Phase

PCD

1/2

CompoundGliclazide / Metformin

Target

Therapeutic areas

T2 diabetes

Phase

PCD

1/2

CompoundBisoprolol / Perindopril / Amlodipine

Target

Therapeutic areas

Hypertension

Phase

PCD

1/2

CompoundDapagliflozin / Gliclazide
(2 formulations)

Target

Therapeutic areas

T2 diabetes

Phase

PCD

1/2

PCD = Preclinical development phase, 1/2 = Phase 1/2, 2 = Phase 2, 3 = Phase 3, RA = Under regulatory authorities evaluation
* Not Disclosed

Download our development pipeline

Our development pipeline

• Oncology

• Neurology

• Cardiometabolism & Venous diseases